- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF)(“BriaCell”).
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF)(“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX Venture Exchange at an average purchase price of $0.083 per Share for an aggregate purchase price of $140,575 (the “Acquisition”) as disclosed on SEDI.ca.
Prior to the Acquisition, Bondarenko previously reported holding 26,745,500 common shares of BriaCell, representing approximately 13.5% of BriaCell’s issued and outstanding common shares. As a result of the Acquisition of the Shares, Bondarenko now has beneficial ownership of an aggregate of 28,443,500 common shares, representing approximately 14.48% of BriaCell’s issued and outstanding common shares.
Bondarenko has acquired these securities for investment purposes and may increase or decrease his beneficial ownership or control over securities of BriaCell as circumstances or market conditions warrant.
This news release is issued pursuant to National Instrument 62-103, The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. A copy of the early warning report will appear with BriaCell’s documents on the System for Electronic Document Analysis and Retrieval at www.sedar.com.
BriaCell‘s head office is located at 3rd Floor, Bellevue Centre, 235-15th Street, West Vancouver, British Columbia V7T 2X1.
For further information or to request a copy of the early warning report, please contact:
Jamieson Bondarenko
416-427-7998
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: www.globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.